European Pharmaceutical Review

DECEMBER 20, 2023

1 The changes form part of the 2020 Pharmaceutical Strategy for Europe will impact pharma and biopharma companies operating in Europe. The second is an adjustment of unmet need categorisation required for RDP extension; unmet need definition now encompasses ‘meaningful’ impact patient outcomes (notably including quality of life).

Biopharma 84

Biopharma Pharmaceutical Medicine Manufacturing 84

European Pharmaceutical Review

DECEMBER 19, 2022

Nonetheless, some stakeholders remain concerned with this new approach given the complexity of biological medicines and the need for patients to be treated individually and have called for further discussions with regulators and all stakeholders. Directive 2001/83 (as amended). EMA Biosimilars Q&A.

Medicine 52

Medicine Biopharma Safety Food 52

European Pharmaceutical Review

DECEMBER 12, 2023

As a biotech, what work does Innate Pharma do in the biopharma industry? IPH5201 is being investigated in a Phase II trial, MATISSE, in combination with durvalumab (anti-PD-L1) and chemotherapy, in patients with resectable early-stage NSCLC. Innate Pharma also developing IPH5201 in collaboration with AstraZeneca. An ORR of 46.4

Pharma 107

Pharma Engineering Safety Patients 107

PM360

OCTOBER 5, 2023

Later in his career he transitioned to the agency side and launched Weisscom Partners in 2001, which ultimately evolved into Real Chemistry. Director US Marketing and Patient Engagement, argenx US, Inc. Weiss has also made substantial efforts to give back to the community at large. Cardiology: Bradley A.

Education 52

Education Marketing Media Biopharma 52

PM360

AUGUST 24, 2023

Each of their trailblazing efforts result in much more than personal or organization success, it results in better quality of life for patients, better care options for healthcare providers, and happier and healthier people around the world.” Director US Marketing and Patient Engagement, argenx US, Inc. Braun Medical, Inc.

Marketing 52

Marketing Education Media Healthcare 52

Pharmaceutical Technology

FEBRUARY 20, 2023

Hans Bunschoten: Viroclinics was founded in 2001, spun out of a university setting. The capabilities of Viroclinics and DDL allowed us to rapidly test repurposed drugs, new vaccines and antiviral solutions for the prevention and treatment of patients affected by COVID-19 in 2020. Can you tell us a little bit about Viroclinics-DDL?

Healthcare 52

Healthcare Healthcare Medicine Biopharma 52